Daiichi Sankyo
Rose Talarico has extensive experience in the pharmaceutical industry, with a focus on product communications and stakeholder engagement. Rose is currently serving as the Director of Global Product Communications at Daiichi Sankyo, Inc. Prior to that, they held the position of Director of Global Product Communications at Alexion Pharmaceuticals, Inc. In 2006, they joined Bayer as the Director of US Communications, Oncology, where they led the development and positioning of Bayer's oncology portfolio and pipeline. Additionally, Talarico served as the Deputy Director of Communications at Novo Nordisk from 2005 to 2006 and at Pharmacia Corporation (now part of Pfizer Inc) from 1999 to 2002. Throughout their career, Talarico has demonstrated a passion for challenging corporate norms to improve patient outcomes.
Rose Talarico holds a Bachelor's degree in Marketing from Seton Hall University. No additional education history is provided.
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.